Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists

BACKGROUND: Stage III N2 non-small cell lung cancer (NSCLC) is a very heterogeneous disease associated with a poor prognosis. A number of therapeutic options are available for patients with Stage III N2 NSCLC, including surgery [with neoadjuvant or adjuvant chemotherapy (CTx)/neoadjuvant chemoradiot...

Descripción completa

Detalles Bibliográficos
Autores principales: Glatzer, Markus, Leskow, Pawel, Caparrotti, Francesca, Elicin, Olgun, Furrer, Markus, Gambazzi, Franco, Dutly, André, Gelpke, Hans, Guckenberger, Matthias, Heuberger, Jürg, Inderbitzi, Rolf, Cafarotti, Stefano, Karenovics, Wolfram, Kestenholz, Peter, Kocher, Gregor Jan, Kraxner, Peter, Krueger, Thorsten, Martucci, Francesco, Oehler, Christoph, Ozsahin, Mahmut, Papachristofilou, Alexandros, Wagnetz, Dirk, Zaugg, Kathrin, Zwahlen, Daniel, Opitz, Isabelle, Putora, Paul Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article on Radiotherapy in Thoracic Malignancies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107728/
https://www.ncbi.nlm.nih.gov/pubmed/34012806
http://dx.doi.org/10.21037/tlcr-20-1210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8107728/
https://www.ncbi.nlm.nih.gov/pubmed/34012806
http://dx.doi.org/10.21037/tlcr-20-1210

Ejemplares similares